February marks a significant milestone in Australian healthcare history. Twenty years ago, on 9 February 2006, the Federal Parliament voted to overturn a political block on mifepristone, returning authority over reproductive medication to medical experts.
While the vote was a historic victory, the path from legislation to actual patient access was not immediate. In the years following the decision, several hurdles remained:
- Commercial Barriers: Due to the heated public debate, pharmaceutical companies were initially hesitant to supply the medication in Australia.
- Administrative Burdens: Access was initially limited to a small number of “Authorised Prescribers” who had to apply for individual permission from the TGA.
- Geographic Inequality: Strict registration requirements for both doctors and pharmacists proved particularly challenging for access in regional and rural Australia.
At MSI Australia, we recognised that a legal right is only meaningful if it is accessible. In 2012, we established our pharmaceutical subsidiary, MS Health, which successfully registered the medication in Australia for the first time. This was followed in 2013 by its inclusion on the Pharmaceutical Benefits Scheme (PBS), ensuring affordability for all.
Today, with nearly 500,000 prescriptions dispensed and the final restrictive “red tape” removed in 2023, medical abortion is a routine part of Australian healthcare. As we look back, we celebrate the persistence of the advocates, clinicians, and policymakers who ensured that healthcare remains in the hands of the experts.
For a detailed look at this 20-year timeline, read the full article in InSight+ here: https://insightplus.mja.com.au/2026/6/an-important-anniversary-in-the-history-of-womens-reproductive-healthcare/
